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Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease that has emerged as the most prevalent form
of late-life dementia in humans [1]. Production of
amyloid-b (Ab) from the amyloid precursor protein (APP)
and its subsequent accumulation, aggregation and deposi-
tion in the brain are central events in the pathogenesis of
AD [1]. Cerebral amyloid angiopathy (CAA) is a major
pathological feature of AD where amyloid spreads and
deposits throughout the blood vessel walls in the central
nervous system. These pathogenic events induce a specific
clinical presentation profile including cerebral hemorrhage,
stroke, ischemic infarctions, subarachnoid hemorrhage,
seizures, cognitive impairment and dementia [2]. While
Ab is a key molecule in AD, epidemiological studies have
shown that several well-established risk factors for AD,
including diabetes mellitus, atherosclerosis, stroke, hyper-
tension, transient ischemic attacks, microvessel pathology
and smoking, have a vascular component that reduces
cerebral perfusion [3]. In fact, detection of regional
cerebral hypoperfusion through neuroimaging techniques
can preclinically identify individuals at risk for AD.
Further, cerebral hypoperfusion precedes hypometabolism,
cognitive decline, and neurodegeneration in AD [3].
Therefore, disturbance of cerebrovascular system is likely a
major contributor to AD pathogenesis. Among the three
human apolipoprotein E (apoE) isoforms (E2, E3 and E4),
APOE4 is the strongest genetic risk factor for late-onset
AD. The most consistent finding that differentiates apoE4
from apoE3 is their respective roles in brain Ab clearance,
where apoE4 is less efficient than apoE3 in promoting Ab
clearance [4]. In addition, APOE4 also increases the risk
for CAA and vascular dementia [4]. Because apoE4 is
known to damage blood-brain barrier (BBB) integrity and
reduces small cerebral vessels [5], apoE is likely involved in
the maintenance of cognitive function through regulating
the function of cerebrovascular systems.
Materials and methods
We generated conditional knockout mice deleting a major
apoE and Ab receptor LRP1 in vascular mural cells
(smLRP1-KO), which include smooth muscle cells and
pericytes. These mice were further bred to the background
of amyloid model mice APP/ PS1. Cerebral blood flow,
behaviors and Ab metabolism were compared among
human APOE isoform (E2, E3 and E4)-targeted replace-
ment (TR) mice and between smLRP1-KO mice and wild-
type littermate controls at young and old ages.
Results
We found that cerebral blood flow and memory perfor-
mance are reduced, while endogenous Ab levels are
elevated, in aged APOE4-TR mice compared to APOE3-
TR mice and in smLRP1-KO mice compared to controls.
When crossed with APP/PS1 mice, deletion of LRP1 in
vascular mural cells exacerbated Ab deposition both in the
cortical parenchyma as amyloid plaques and along the
cerebral vessels as CAA [6].
Conclusions
Our results demonstrate that the presence of APOE4 or
an absence of apoE receptor LRP1 leads to cerebrovascular
defects, which compromise Ab clearance machinery
resulting in Ab accumulation in the brain. The resulting
Ab aggregation and deposition further exacerbate cerebro-
vascular dysfunction in AD.
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